Dianthus Therapeutics
DNTH
84.88
-0.52
-0.61%
Dianthus Therapeutics
US · DNTH
#2155 by market cap
Listed 1970
84.88
-0.52
-0.61%
Live - 5344 symbols - heartbeat 374s ago
· 2026-10-07 21:26
After-hours
84.88
0.00%
Overnight
85.24
+0.42%
- Market cap
- 4.75B
- P/E (TTM)i
- -20.02
- P/Bi
- 4.05
- EPSi
- -4.20
- Div yieldi
- 0.00%
- 52W posi
- 61%
Reader sentiment
Are you bullish or bearish on DNTH?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 13 analysts
Buy
Avg price target
142.82 +68.3%
Price target rangecurrent 84.88
Low122.00
Avg142.82
High200.00
Buy 100%
Hold 0%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-10-01 | H.C. Wainwright | -- | BUY | 158.00 |
| 2026-09-29 | LifeSci Capital | -- | BUY | 125.00 |
| 2026-09-24 | J.P. Morgan | -- | BUY | -- |
| 2026-09-18 | William Blair | -- | BUY | -- |
| 2026-09-11 | J.P. Morgan | -- | BUY | 135.00 |
| 2026-09-04 | Citi | -- | BUY | 156.00 |
| 2026-08-13 | Stifel | -- | BUY | 133.00 |
| 2026-08-10 | Evercore | -- | BUY | 134.00 |
| 2026-08-06 | Truist Financial | -- | BUY | 128.00 |
| 2026-08-06 | Stifel | -- | BUY | 133.00 |
| 2026-08-06 | H.C. Wainwright | -- | BUY | 158.00 |
| 2026-08-05 | TD Cowen | -- | BUY | 150.00 |
| 2026-08-05 | Wells Fargo | -- | BUY | 135.00 |
| 2026-08-05 | Wedbush | -- | BUY | 122.00 |
| 2026-08-05 | Clear Street | -- | BUY | 130.00 |
| 2026-08-05 | Guggenheim | -- | BUY | 200.00 |
| 2026-08-04 | TD Cowen | -- | BUY | 150.00 |
| 2026-08-04 | LifeSci Capital | -- | BUY | 125.00 |
| 2026-08-04 | William Blair | -- | BUY | -- |
| 2026-08-04 | Clear Street | -- | BUY | 130.00 |
| 2026-07-01 | H.C. Wainwright | -- | BUY | 130.00 |
| 2026-06-17 | Wells Fargo | -- | BUY | 135.00 |
| 2026-06-16 | Wells Fargo | -- | BUY | 135.00 |
| 2026-06-15 | Truist Financial | -- | BUY | -- |
| 2026-06-15 | Wedbush | -- | BUY | 105.00 |
Quant vs Street three independent views, side by side
Momentum strategy signal
Buy
Analyst consensus
Buy
All 2 views agree: bullish.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
Quote time 2026-10-07 21:26:06 · For reference only, not investment advice and not tailored to your situation.